Top-News
Pharmazeutika USA

Durect Aktie

Aktie
WKN:  A3DZZ2 ISIN:  US2666055007 US-Symbol:  DRRX
0,85 €
+0,10 €
+13,33%
04.12.24
Handeln Depot/Watchlist
Aktienanzahl *
29,83 Mio.
Marktkapitalisierung *
24,75 Mio. €
Streubesitz
-
Index-Zugehörigkeit
Nasdaq Composite Index
IR-Website
zur Website
*Stand: 31.03.2024

Durect News

25.11.24 - PR Newswire
DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million
DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million PR Newswire
13.11.24 - PR Newswire
DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update
DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update PR Newswire
06.11.24 - PR Newswire
DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update
DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update PR Newswire
17.10.24 - PR Newswire
DURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024
DURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024 PR Newswire
25.09.24 - PR Newswire
DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis
DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-​associated Hepatitis PR Newswire
04.09.24 - PR Newswire
DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference
DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference PR Newswire
13.08.24 - PR Newswire
DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update
DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update PR Newswire
07.08.24 - PR Newswire
DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update
DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update PR Newswire
21.05.24 - PR Newswire
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-​Associated Hepatitis PR Newswire
13.05.24 - PR Newswire
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update PR Newswire
07.05.24 - PR Newswire
DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update
DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update PR Newswire
30.04.24 - PR Newswire
DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis
DURECT Corporation Announces Late-​Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-​Associated Hepatitis PR Newswire
27.03.24 - PR Newswire
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update PR Newswire
20.03.24 - PR Newswire
DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update PR Newswire
04.03.24 - PR Newswire
DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada
DURECT and Charles River Laboratories Enter into Co-​Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada PR Newswire
22.02.24 - PR Newswire
Thinking about buying stock in Vermilion Energy, Staffing 360 Solutions, DURECT, Root Inc, or Ventyx Biosciences?
Thinking about buying stock in Vermilion Energy, Staffing 360 Solutions, DURECT, Root Inc, or Ventyx Biosciences? PR Newswire
07.02.24 - PR Newswire
DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference PR Newswire
09.11.23 - PR Newswire
DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update
DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update PR Newswire
07.11.23 - PR Newswire
DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality
DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-​Associated Hepatitis with Promising Effect on Mortality PR Newswire
31.08.23 - PR Newswire
DURECT Corporation Announces Presentations in Upcoming Investor Conferences
DURECT Corporation Announces Presentations in Upcoming Investor Conferences PR Newswire

Newssuche

Videos

newspaper
10.12.24 -10,01%
Technical Trading: Bitcoin Short Chance, weil
Bitcoin Short Typ: Turbo Open End WKN: VC7P6B Hebel: 2,20 Laufzeit: OpenEnd Einstieg: Market ... Mehr »